✦ LIBER ✦

NICE guidance on trastuzumab for the treatment of HER2-positive metastatic gastric cancer

✍ Scribed by Joanne Holden; Zoe Garrett; Andrew Stevens

Book ID: 117785528
Publisher: The Lancet
Year: 2011
Tongue: English
Weight: 47 KB
Volume: 12
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(10)70276-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Trastuzumab for the Treatment of HER2-Po

Trastuzumab for the Treatment of HER2-Positive Metastatic Gastric Cancer

✍ Spackman, Eldon; Rice, Stephen; Norman, Gill; Suh, Dong-Churl; Eastwood, Alison; 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 260 KB

NICE guidance on aflibercept for treatme

NICE guidance on aflibercept for treatment of metastatic colorectal cancer

✍ Elsada, Ahmed; George, Elisabeth; Adler, Amanda 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 52 KB

Trastuzumab: Anti-HER2 Antibody for Trea

Trastuzumab: Anti-HER2 Antibody for Treatment of Metastatic Breast Cancer

✍ Wendy M. Wong 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB

PCN20 Analysis of Using Trastuzumab for

PCN20 Analysis of Using Trastuzumab for the Treatment of Advanced Gastric Cancer With HER2 Positive

✍ Lechuga, D.; Gay, J.G.; Alva, M.; Sanchez-kobayashi, R. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

FDA Approval: Ado-Trastuzumab Emtansine

FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

✍ Amiri-Kordestani, L.; Blumenthal, G. M.; Xu, Q. C.; Zhang, L.; Tang, S. W.; Ha, 📂 Article 📅 2014 🏛 American Association for Cancer Research 🌐 English ⚖ 262 KB

Duration of trastuzumab for HER2-positiv

Duration of trastuzumab for HER2-positive breast cancer

✍ Montemurro, Filippo; Aglietta, Massimo 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 203 KB